deltatrials
Completed PHASE3 NCT00180310

SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions

Sponsor: Abbott Medical Devices

Conditions Coronary Artery Disease Coronary Disease Coronary Restenosis
Interventions TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent XIENCE V® Everolimus Eluting Coronary Stent
Updated 7 times since 2017 Last updated: Jul 18, 2011 Started: Jul 31, 2005 Primary completion: Jul 31, 2007 Completion: Feb 28, 2011

A PHASE3 clinical study on Coronary Artery Disease and Coronary Disease, this trial is completed. The trial is conducted by Abbott Medical Devices and has accumulated 7 data snapshots since 2005. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Dec 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Jun 2018 — Dec 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abbott Medical Devices
Data source: Abbott Medical Devices

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark, Aarhus, Denmark, Amsterdam, Netherlands, Antwerp, Belgium, Auckland, New Zealand, Bad Oeynhausen, Germany, Bad Segeberg, Germany, Basel, Switzerland, Breda, Netherlands, Cape Town, South Africa and 18 more location s